Experimental Pitfalls Sample Clauses

Experimental Pitfalls. The effective and efficient evaluation of the actual mask order of cryptographic implementations remains an open problem due to several evaluation pitfalls. Effectivity-wise, when evaluating a masking scheme via the measured power consumption, we face the pitfall of the limited attack scope. That is, a particular attack technique in use may fail to exploit the available leakage due to e.g. an unsuitable choice of intermediate values or an incorrect power model assumption7. Moreover, introducing additional countermeasures on top of the masking scheme may render particular exploitation techniques ineffective, while the implementation remains vulnerable to different lines of attack. In order to tackle this issue, the research community followed several approaches. Prior research established generic side-channel distinguishers such as Mutual Information Analysis (MIA) [4], the Kolmogorov-Xxxxxxx and the Cr`amer-von Mises tests [48, 49], which require minimal assumptions about the noise and the power model of the device under test. On the other side of the spectrum, Xxxxxxxxx et al. [44] proposed an evaluation framework assuming the strongest possible adversary, equipped with extensive profiling capabilities and Bayesian templates.
AutoNDA by SimpleDocs
Experimental Pitfalls. The effective and efficient evaluation of the actual mask order of cryptographic implementations remains an open problem due to several evaluation pitfalls. Effectivity-wise, when evaluating a masking scheme via the measured power consumption, we face the pitfall of the limited attack scope. That is, a particular attack technique in use may fail to exploit the available leakage due to e.g. an unsuitable choice of intermediate values or an incorrect power model assumption7. Moreover, introducing additional countermeasures on top of the masking scheme may render particular exploitation techniques ineffective, while the implementation remains vulnerable to different lines of attack. In order to tackle this issue, the research community followed several approaches. Prior research established generic side-channel distinguishers such as Mutual Information Analysis (MIA) [4], the Kolmogorov-Xxxxxxx and the Cr`amer-von Mises tests [48, 49], which require minimal assumptions about the noise and the power model of the device under test. On the other side of the spectrum, Xxxxxxxxx et al. [44] proposed an evaluation framework assuming the strongest possible adversary, equipped with extensive profiling capabilities and Bayesian templates. While being effective, the aforementioned approaches focus on leakage exploitation and perform key recovery, which may require a large number of traces. Thus, they face the efficiency pitfall w.r.t. computational and storage requirements. Note that this increased demand for resources is magnified when inserting extra countermeasures in a masked implementation. Thus, it can be difficult to decide with confidence whether the masking order is reduced or not. In order to evaluate the effective masking order, we opt for a more recent app- xxxxx called leakage detection methodology [31]. This approach focuses on leakage detection and disregards exploitation. Thus, the acquisition and the computa- tional cost is reduced while the methodology can retain its generic nature. Despite the gain achieved via decoupling detection and exploitation, the leak- age detection methodology still presents challenges w.r.t. efficiency. In the con- text of software masking, we need to combine multiple time samples in order to evaluate the masked implementation. Thus, we rely on the work by Xxxxxxxxx et al. [42], who extended the leakage detection methodology into higher-order evaluations by providing efficient, incremental formulas that can handle the com- putation involved wi...

Related to Experimental Pitfalls

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Projects The Annexes attached hereto describe the specific projects and the policy reforms and other activities related thereto (each, a “Project”) that the Government will carry out, or cause to be carried out, in furtherance of this Compact to achieve the Objectives and the Compact Goal.

Time is Money Join Law Insider Premium to draft better contracts faster.